Catherine Kolonko

The United Kingdom's National Institute for Health and Care Excellence (NICE) is recommending Sovaldi as a cost-effective option to treat some people who have chronic hepatitis C.

An emerging epidemic of acute hepatitis C threatens the country's younger population, which experienced a significant hike in the number of cases during a recent 6-year period, according to a compound study that looked at trends of the disease among youth.

Hepatitis C genotype 1 is the most common of half a dozen genotypes of the virus and accounts for nearly half of all cases, according to results from global analysis conducted by researchers in the United Kingdom.

A combination oral treatment of sofosbuvir and ribavirin resulted in high cure rates of hepatitis C among a patient population that also was infected with HIV.

The US Senate Finance Committee recently requested detailed pricing information on Sovaldi (sofosbuvir), its breakthrough oral treatment for hepatitis C.

Japanese regulators have approved an all-oral daclatsvir plus asunaprevir drug regimen developed by Bristol-Meyers Squibb to treat patients with genotype 1 chronic hepatitis C.

A recent study found that the hepatitis C virus decays during treatment with telaprevir faster in the bloodstream than it does in the liver, a discovery that could help pinpoint how long a patient needs to take medicine to rid the virus from the body.

Study results show hepatic decompensation is more common in people who have both HIV and hepatitis C virus (HCV) compared to those infected only with HCV, an indication that early HCV treatment among coinfected patients is needed.

Scientists have mapped the structure of a hepatitis C virus surface protein that is responsible for binding to host liver cells, leading to virus entry.

Most children with hepatitis C contract the virus through transmission from their chronically infected mothers, either in the womb or at birth, particularly when an expectant mother also is HIV-positive.

The FDA has granted priority review for a New Drug Application submitted by AbbVie Inc. for its all-oral, interferon-free therapy for patients with chronic genotype 1 hepatitis C virus infection.

The US Food and Drug Administration partially lifted a clinical hold on a hepatitis C drug under development by Achillion Pharmaceuticals, clearing the way for a restart of the company's clinical trials of sovaprevir.

People from the Baby Boom generation covered under Medicare can now get one-time screening for hepatitis C, according to a memo from the Centers for Medicare & Medicaid Services.

Noting that this year marks the 25th anniversary of the discovery of hepatitis C, health officials ramped up a public awareness campaign during the month of May to encourage more testing for hepatitis among at-risk populations.

A Swedish pharmaceutical company has been granted approval by the European Commission to market the drug simeprevir for the treatment of genotype 1 and 4 chronic hepatitis C infection.

A project to expand hepatitis C treatment by equipping primary care doctors with telemedicine tools more than doubled the proportion of patients expected to receive treatment in Arizona and Utah, according to a recently released government report.

An all-oral antiviral drug combination that included ombitasvir and dasabuvir with and without ribavirin resulted in high cure rates among patients with hepatitis C virus infections in first-time treatments for the disease, according to an article published in the May 4, 2014, issue of the New England Journal of Medicine.

A multipronged approach built around screening, education, community outreach, and expanded access to care is critical to reducing the prevalence of hepatitis C in the African-American community.

Company is seeking FDA approval for its all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 hepatitis C.

New guidance from the WHO includes nine key recommendations covering screening, treatment, alcohol use assessment and counseling, and measures to prevent transmission of the virus.

Federal plan includes new hepatitis C testing recommendations, enhanced hepatitis B education and outreach initiatives, and increased efforts at surveillance to monitor disease transmission, and other components.

Fitful nights of sleeplessness and daytime fatigue were more common among people with hepatitis C regardless of whether they had cirrhosis of the liver when compared to the healthy control group involved in a small study.

Nearly one-third of the population in the US who have hepatitis C are people who are incarcerated; however, prevalence of the disease among this group has dipped in recent years.

Study results show hepatic decompensation is more common in people who have both HIV and hepatitis C virus (HCV) compared to those infected only with HCV, an indication that early HCV treatment among coinfected patients is needed.

The California Technology Assessment Forum recently evaluated the comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis c infection.

Estimates from a national survey indicate that there are 2.7 million people in the United States who are chronically infected with Hepatitis C virus (HCV), a decline over previous years.

Hepatitis C often goes unreported on death certificates and people who have the virus are more likely to die younger than those who don't, according to results from 2 mortality studies.

Scientists have mapped the structure of a hepatitis C virus surface protein that is responsible for binding to host liver cells, leading to virus entry.

The Food and Drug Administration has updated a drug warning label and medication guide for Victrelis (boceprevir) after receiving reports of abnormally low levels of red and white blood cells in patients who received it as part of combination treatment for hepatitis C.

Researchers wanting to untangle the genetic aspect of the hepatitis C virus that allows it to resist treatment discovered that one particular DNA variant acts like a powerful weapon that helps some people to better fight the disease.